医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

New Cancer Hospital Chris O’Brien Lifehouse in Australia Goes Live with the MetaVision Clinical Information System

2015年05月27日 PM05:29
このエントリーをはてなブックマークに追加


 

BRISBANE, Australia

iMDsoft announced that Chris O’Brien Lifehouse went live with the MetaVision clinical information system in their critical care and post anaesthesia recovery units. The MetaVision anaesthesia information management system is slated to go live in the near future.

Lifehouse, a world-class not-for-profit integrated cancer treatment centre in Sydney, opened its doors in November 2013. The hospital is among the first to go live with MetaVision 6, the latest version of iMDsoft’s CIS, which features a new user interface and advanced electronic medication management among its enhancements.

Designed to meet the unique needs of the critical care environment, MetaVision generates complete and accurate electronic medical records and includes advanced tools for clinical assessment, treatment and care planning. The system provides data continuity across departments, ensuring no information is missed in the handover process.

Using MetaVision, hospitals can comply with clinical guidelines for best practices such as the ANZCA endorsed guidelines and the National Safety and Quality Health Service standards, and streamline data collection and export for reporting requirements such as ANZICS. Lifehouse joins other leading organisations using MetaVision, including New South Wales Health, Queensland Health, ACT Health, Fiona Stanley Hospital and Sydney Adventist Hospital.

“The partnership between the Chris O’Brien Lifehouse and iMDsoft to implement the MetaVision clinical information system has been a great success. Our mission is to provide world leading, integrated care for cancer patients and MetaVision provides a flexible, user friendly system to support our staff in delivery of that care. The system is now live in the ICU and PARU, with Anaesthetics coming online in the near future. Our clinicians and patients benefit from continuity of information, availability of data for reporting and clinical research and a system that has been configured to meet the needs of our organisation,” said Professor Michael Boyer, Chief Clinical Officer, Chris O’Brien Lifehouse.

“We are proud to be a part of Lifehouse’s vision to provide uncompromising care to patients as they live with and recover from cancer,” said Lars-Oluf Nielsen, CEO of iMDsoft. ”As Lifehouse hospital continues to introduce innovations in patient treatment, together we can seek to accommodate new requirements for their intensive care and anaesthesia environments,” said Lars-Oluf Nielsen, CEO of iMDsoft.

MetaVision will be presented at CICM in Darwin, Friday 29th to Sunday 31st May.

Would you like to support the Chris O’Brien Lifehouse in their mission to provide world class cancer care? Please visit the following page to see all of the current fund-raising activities underway with the Lifehouse team: http://www.mylifehouse.org.au/How_you_can_help/Upcoming_events/

iMDsoft is proud to support Lifehouse in the Sydney Ride to Conquer Cancer: http://www.mylifehouse.org.au/How_you_can_help/Events/Event/The_Ride_to_Conquer_Cancer/

About iMDsoft

iMDsoft is a leading provider of Clinical Information Systems for critical, perioperative, and acute care environments. The company’s flagship family of solutions, the MetaVision Suite, was first implemented in 1999. Hospitals and health networks worldwide use MetaVision to improve care quality and enhance financial results. The system promotes compliance with protocols and best practices, streamlines reporting and supports clinical research. To learn more about iMDsoft, visit www.imd-soft.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150527005587/en/

CONTACT

iMDsoft
Anne Belkin, +781-4495567
Director of Marketing
anne.belkin@imd-soft.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表